Entropy Technologies’s Regeneron Pharmaceuticals REGN Stock Holding History

Entropy Technologies’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.13M	Buy	2,753 +1,747	+174%	+$1.34M	0.1%	273
2025 Q4	$777K	Buy	+1,006	New	+$683K	0.04%	448
2025 Q3	–	Sell	-7,196	Closed	-$3.78M	–	1053
2025 Q2	$3.78M	Sell	7,196 -1,894	-21%	-$1.06M	0.3%	87
2025 Q1	$5.77M	Buy	9,090 +3,790	+72%	+$2.61M	0.56%	35
2024 Q4	$3.78M	Buy	5,300 +4,900	+1,225%	+$4.11M	0.39%	60
2024 Q3	$420K	Buy	+400	New	+$445K	0.04%	481

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Entropy Technologies's REGN Position: Q1 2026 in Review

Entropy Technologies increased its Regeneron Pharmaceuticals (REGN) stake by 174% in Q1 2026, buying an estimated $1.34M and bringing the position to 2,753 shares worth $2.13M. The position accounts for 0.1% of the portfolio, ranked #273.

Entropy Technologies first reported a position in REGN in Q3 2024 and has held it in 6 quarters since. The position peaked at $5.77M in Q1 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Entropy Technologies held 2,753 shares of Regeneron Pharmaceuticals worth $2.13M as of Q1 2026.
Entropy Technologies bought 1,747 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.34M.
Regeneron Pharmaceuticals made up 0.1% of Entropy Technologies's portfolio in Q1 2026, its #273 holding.
Entropy Technologies first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
Entropy Technologies's Regeneron Pharmaceuticals position peaked at $5.77M in Q1 2025.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.